What We Do Section 1
Universities, research institutions and individual researchers are generating biologic patient data and other determining patient characteristics at an unprecedented rate. Through our partner Emerald Logic, we can let the data determine the critical associations pertinent to the research and identify the critical biomarkers and algorithms that matter. This is a completely novel and proprietary approach to medical discovery, which can then be validated independent of the discovery method.
What We Do Section 2
These discoveries are then validated with additional hold-out data sets. Such hold-out data sets may be derived from existing studies or may come from new research commissioned by BlueprintBio. Once sufficient validation has been achieved, the discoveries are then delivered to our intellectual property specialists.
What We Do Section 3
Our legal team Lead by Dr. James Hill then builds an intellectual property wall around the discoveries in order to protect both the discovery itself and the methods used to produce the asset. This strategic application of patents, trade secrets and other protection features allow BlueprintBio to publicly announce its findings with the medical community.
What We Do Section 4
BlueprintBio contacts leading research and clinical authorities in the field of the discovery. The company collaborates with these experts on articles to be published in peer-reviewed journals. This establishes credibility and creates exposure of both the discovery and potential applications to the medical and pharmaceutical communities.
What We Do Section 5
The proprietary assets are then made available to companies who wish to take them to market. This can be done through license and royalties, joint ventures, or in some cases through the formation of a wholly-owned subsidiary created for the purpose of bringing the discovery to market.